1 November 2024

Director/PDMR Shareholding

Bioventix plc 

(“Bioventix” or “the Company”) 

Director Dealing 

 

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 30 October 2024 that on 30 October 2024 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 300 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at an average price of 3,330 pence per Ordinary Share (the “Purchase”).

 

Following the Purchase, Bruce Hiscock has a beneficial interest in 1,089 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company. 

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details. 

 

 

For further information please contact: 

 

Bioventix plc 

Peter Harrison 

 

Chief Executive Officer 

Tel: 01252 728 001 

Cavendish 

Geoff Nash / Abigail Kelly

Nigel Birks / Harriet Ward 

 

Corporate Finance 

ECM 

Tel: 020 7220 0500 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 

  

1 

Details of the person discharging managerial responsibilities / person closely associated 

a) 

Name 

Bruce Hiscock 

2. 

Reason for the Notification 

a) 

Position/status 

Chief Financial Officer 

b) 

Initial notification/Amendment 

Initial notification 

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

a) 

Name 

Bioventix Plc 

b) 

LEI 

213800225MHX7LZQY108 

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

a) 

Description of the Financial instrument, type of instrument 

Ordinary Shares of 5 pence each 

Identification code 

GB00B4QVDF07 

b) 

Nature of the transaction 

Purchase of Ordinary Shares 

c) 

Price(s) and volume(s) 

300 Ordinary Shares 

3,330 pence 

d) 

Aggregated information: 

 

·     Aggregated volume 

 

·     Price 

Purchase of 300 Ordinary Shares at 3,330 pence each 

e) 

Date of the transaction 

30 October 2024 

f) 

Place of the transaction 

London Stock Exchange, AIM Market (XLON)